BioSpace News Archive

Business

Dysfunctional Tissue Resident CD8 T Cells Have Opposite Effect on Elderly Patients

A study recently conducted at Mayo Clinic showed that dysfunctional Tissue Resident Memory (TRM) CD8 T cells are actually working against the elderly, reducing immunity and enabling residual chronic lung issues after respiratory infections such as COVID-19.

November 13, 2020
·
3 min read
·
Heather McKenzie
Unmet Need in Dry Eye Disease Market Leaves Room for Other Drugmakers to Step In

Dry eye disease remains a major problem among people and companies are still finding a way to cure it. The unmet need leads to numerous innovations every year.

November 13, 2020
·
3 min read
·
Alex Keown
Drug Development

Nkarta Treats First Patient in Phase I Trial for Relapsed/Refractory AMLS and MDS

Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.

November 13, 2020
·
3 min read
·
Brandon May
Job Trends

How Effective Will Lilly’s Bamlanivimab be in the Battle Against COVID-19?

Despite the greenlight from the U.S. Food and Drug Administration as an emergency treatment, there are some questions about how effective the treatment will actually prove to be due to labeling limitations.

November 13, 2020
·
3 min read
·
Alex Keown
Business

Sunshine Vitamin Could Help Boost Immunity in Fight Against COVID-19

A recent study found that Vitamin D deficiency may be associated with an increased COVID-19 risk.

November 13, 2020
·
4 min read
·
Kate Goodwin
Biotech Investors Rolling the Dice with 250% SPAC Surge

Emerging biotech companies have been finding creative ways to explode onto the stock exchange during the COVID-19 pandemic.

November 13, 2020
·
2 min read
·
Heather McKenzie
Drug Development

Could Synairgen’s SNG001 Be an Effective COVID-19 Treatment Option?

Synairgen announced today that its data from the SG016 trial was published in the journal The Lancet Respiratory Medicine. The trial, which included 101 hospitalized COVID-19 patients, looked at SNG001 as a potential treatment.

November 13, 2020
·
3 min read
·
Krystle Vermes
Policy

France’s Medicine Watchdog Indicted Over Sanofi’s Birth Defect-Causing Drug Depakine

Sanofi was formally charged over Depakine, its epilepsy drug, for not taking action when they first discovered the fetal risks when taken by pregnant women.

November 13, 2020
·
3 min read
·
Kate Goodwin
BioMidwest

SSRI Antidepressant Fluvoxamine May Be Effective Early Treatments for COVID-19

A group of Researchers in St. Louis published the results of a clinical trial evaluating antidepressant fluvoxamine, for early treatment for COVID-19.

November 13, 2020
·
3 min read
·
Mark Terry
Business

Accuracy Concerns Continue to Surround Rapid Antigen Tests for COVID-19

There have been some concerns over the accuracy of COVID-19 rapid antigen tests—the clinical diagnostic tests that evaluate for active infections by testing for the presence of the virus’s antigens.

November 13, 2020
·
3 min read
·
Mark Terry